Home > Research > Publications & Outputs > Nanoformulated Bumetanide Ameliorates Social De...

Links

Text available via DOI:

View graph of relations

Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder. / Lv, Hui; Gu, Xiao; Shan, Xingyue et al.
In: Frontiers in Immunology, Vol. 13, 870577, 23.05.2022.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Lv, H, Gu, X, Shan, X, Zhu, T, Ma, B, Zhang, H-T, Bambini-Junior, V, Zhang, T, Li, W-G, Gao, X & Li, F 2022, 'Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder', Frontiers in Immunology, vol. 13, 870577. https://doi.org/10.3389/fimmu.2022.870577

APA

Lv, H., Gu, X., Shan, X., Zhu, T., Ma, B., Zhang, H.-T., Bambini-Junior, V., Zhang, T., Li, W.-G., Gao, X., & Li, F. (2022). Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder. Frontiers in Immunology, 13, Article 870577. https://doi.org/10.3389/fimmu.2022.870577

Vancouver

Lv H, Gu X, Shan X, Zhu T, Ma B, Zhang HT et al. Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder. Frontiers in Immunology. 2022 May 23;13:870577. doi: 10.3389/fimmu.2022.870577

Author

Lv, Hui ; Gu, Xiao ; Shan, Xingyue et al. / Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder. In: Frontiers in Immunology. 2022 ; Vol. 13.

Bibtex

@article{98865ff743834814b77aa40ed2007ef5,
title = "Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder",
abstract = "Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder with few medication options. Bumetanide, an FDA-approved diuretic, has been proposed as a viable candidate to treat core symptoms of ASD, however, neither the brain region related to its effect nor the cell-specific mechanism(s) is clear. The availability of nanoparticles provides a viable way to identify pharmacological mechanisms for use in ASD. Here, we found that treatment with bumetanide, in a systemic and medial prefrontal cortex (mPFC) region-specific way, attenuated social deficits in BTBR mice. Furthermore, using poly (ethylene glycol)-poly(l-lactide) (PEG-PLA) nanoparticles [NP(bumetanide)], we showed that the administration of NP(bumetanide) in a mPFC region-specific way also alleviated the social deficits of BTBR mice. Mechanistically, the behavioral effect of NP(bumetanide) was dependent on selective microglia-specific targeting in the mPFC. Pharmacological depletion of microglia significantly reduced the effect of nanoencapsulation and depletion of microglia alone did not improve the social deficits in BTBR mice. These findings suggest the potential therapeutic capabilities of nanotechnology for ASD, as well as the relevant link between bumetanide and immune cells.",
keywords = "Immunology, autism spectrum disorder, bumetanide, nanoparticle, social behavior, microglia",
author = "Hui Lv and Xiao Gu and Xingyue Shan and Tailin Zhu and Bingke Ma and Hao-Tian Zhang and Victorio Bambini-Junior and Tiantian Zhang and Wei-Guang Li and Xiaoling Gao and Fei Li",
year = "2022",
month = may,
day = "23",
doi = "10.3389/fimmu.2022.870577",
language = "English",
volume = "13",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder

AU - Lv, Hui

AU - Gu, Xiao

AU - Shan, Xingyue

AU - Zhu, Tailin

AU - Ma, Bingke

AU - Zhang, Hao-Tian

AU - Bambini-Junior, Victorio

AU - Zhang, Tiantian

AU - Li, Wei-Guang

AU - Gao, Xiaoling

AU - Li, Fei

PY - 2022/5/23

Y1 - 2022/5/23

N2 - Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder with few medication options. Bumetanide, an FDA-approved diuretic, has been proposed as a viable candidate to treat core symptoms of ASD, however, neither the brain region related to its effect nor the cell-specific mechanism(s) is clear. The availability of nanoparticles provides a viable way to identify pharmacological mechanisms for use in ASD. Here, we found that treatment with bumetanide, in a systemic and medial prefrontal cortex (mPFC) region-specific way, attenuated social deficits in BTBR mice. Furthermore, using poly (ethylene glycol)-poly(l-lactide) (PEG-PLA) nanoparticles [NP(bumetanide)], we showed that the administration of NP(bumetanide) in a mPFC region-specific way also alleviated the social deficits of BTBR mice. Mechanistically, the behavioral effect of NP(bumetanide) was dependent on selective microglia-specific targeting in the mPFC. Pharmacological depletion of microglia significantly reduced the effect of nanoencapsulation and depletion of microglia alone did not improve the social deficits in BTBR mice. These findings suggest the potential therapeutic capabilities of nanotechnology for ASD, as well as the relevant link between bumetanide and immune cells.

AB - Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder with few medication options. Bumetanide, an FDA-approved diuretic, has been proposed as a viable candidate to treat core symptoms of ASD, however, neither the brain region related to its effect nor the cell-specific mechanism(s) is clear. The availability of nanoparticles provides a viable way to identify pharmacological mechanisms for use in ASD. Here, we found that treatment with bumetanide, in a systemic and medial prefrontal cortex (mPFC) region-specific way, attenuated social deficits in BTBR mice. Furthermore, using poly (ethylene glycol)-poly(l-lactide) (PEG-PLA) nanoparticles [NP(bumetanide)], we showed that the administration of NP(bumetanide) in a mPFC region-specific way also alleviated the social deficits of BTBR mice. Mechanistically, the behavioral effect of NP(bumetanide) was dependent on selective microglia-specific targeting in the mPFC. Pharmacological depletion of microglia significantly reduced the effect of nanoencapsulation and depletion of microglia alone did not improve the social deficits in BTBR mice. These findings suggest the potential therapeutic capabilities of nanotechnology for ASD, as well as the relevant link between bumetanide and immune cells.

KW - Immunology

KW - autism spectrum disorder

KW - bumetanide

KW - nanoparticle

KW - social behavior

KW - microglia

U2 - 10.3389/fimmu.2022.870577

DO - 10.3389/fimmu.2022.870577

M3 - Journal article

VL - 13

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 870577

ER -